|Mr. Omar S. Ishrak||Chairman & CEO||7.9M||3.3M||62|
|Ms. Karen L. Parkhill||Exec. VP & CFO||3.33M||N/A||53|
|Mr. Michael J. Coyle||Exec. VP and Group Pres of Cardiac & Vascular Group||2.72M||N/A||56|
|Mr. Robert J. W. ten Hoedt||Exec. VP and Group Pres, Europe, Middle East & Africa||2.01M||2.21M||57|
|Mr. Gary L. Ellis||Former Exec. VP of Global Operations & Information Technology||2.41M||3.08M||60|
Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions. The company's Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company's Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Medtronic plc’s ISS Governance QualityScore as of January 1, 2018 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 6; Compensation: 3.